Hypericin
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID), Soligenix, Ellen Kim, MD
Conditions
CTCLCTCL/ Mycosis FungoidesCutaneous T Cell LymphomaCutaneous T-Cell Lymphoma/Mycosis FungoidesHIV InfectionsMycosis FungoidesPlaque PsoriasisPsoriasis
Phase 1
A Phase I Dose Escalation Study of Synthetic Hypericin in HIV-Infected Patients With Less Than 300 CD4 Lymphocytes
CompletedNCT00000645
End: 1994-10-31Target: 32Updated: 2021-11-03
A Pharmacologically Guided Phase I/II Study of Daily Orally Administered Synthetic Hypericin in HIV-Infected Subjects
CompletedNCT00000792
End: 1995-01-31Target: 24Updated: 2021-11-04
Phase 2
PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma
CompletedNCT05380635
Start: 2022-05-09End: 2022-08-16Updated: 2023-06-07
Topical SGX302 for Mild-to-Moderate Psoriasis
CompletedNCT05442190
Start: 2022-12-14End: 2025-11-17Updated: 2026-08-13
Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light
CompletedNCT05872854
Start: 2023-08-21End: 2025-12-22Updated: 2026-02-09
HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
CompletedNCT06149247
Start: 2023-12-05End: 2024-06-27Updated: 2025-08-20